|Mr. Guy MacDonald B.Sc||Chief Exec. Officer, Pres and Director||724.1k||76.73k||58|
|Mr. Christopher Watt||Sr. VP of Fin.||378.72k||N/A||52|
|Dr. Jacques Dumas Ph.D.||Chief Scientific Officer||508.56k||N/A||51|
|Ms. Maria D. Stahl||Sr. VP and Gen. Counsel||456.56k||N/A||46|
|Dr. Patrick T. Horn M.D., Ph.D.||Chief Medical Officer||532.12k||N/A||62|
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Tetraphase Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.